Martin Trbusek

Martin Trbusek

Auto-generated profile, based on publicly available information

Martin Trbusek

University Hospital Brno, Brno, Czech Republic

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2014 in Leukemia
Verified
Journal Article
Open access
JMJ Malcikova
J Malcikova
KSK Stano-Kozubik
K Stano-Kozubik
BTB Tichy
B Tichy
BKB Kantorova
B Kantorova
SPS Pavlova
S Pavlova
MTM Trbusek
M Trbusek
In chronic lymphocytic leukemia (CLL), the worst prognosis is associated with TP53 defects with the affected patients being potentially directed to alternative treatment. Therapy administration was shown to drive the selection of new TP53 mutations in CLL. Using ultra-deep next-generation sequencing (NGS), we performed a detailed analysis of TP53 mutations' clonal evolution. We retrospectively analyzed samples that were assessed as TP53-wild-type (wt) by FASAY from 20 patients with a new TP53 mutation detected in relapse and 40 patients remaining TP53-wt in relapse. Minor TP53-mutated subclones were disclosed in 18/20 patients experiencing later mutation selection, while only one minor-clone mutation was observed in those patients remaining TP53-wt (n=40). We documented that (i) minor TP53 mutations may be present before therapy and may occur in any relapse; (ii) the majority of TP53-mutated minor clones expand to dominant clone under the selective pressure of chemotherapy, while persistence of minor-clone mutations is rare; (iii) multiple minor-clone TP53 mutations are common and may simultaneously expand. In conclusion, patients with minor-clone TP53 mutations carry a high risk of mutation selection by therapy. Deep sequencing can shift TP53 mutation identification to a period before therapy administration, which might be of particular importance for clinical trials.

1 July 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MTMartin Trbusek
Martin Trbusek
JSJana Smardova
Jana Smardova
JMJitka Malcikova
Jitka Malcikova
LSLudmila Sebejova
Ludmila Sebejova
PDPetr Dobes
Petr Dobes
JMJiri Mayer
Jiri Mayer
Purpose: There is a distinct connection between TP53 defects and poor prognosis in chronic lymphocytic leukemia (CLL). It remains unclear whether patients harboring TP53 mutations represent a homogenous prognostic group. Patients and Methods: We evaluated the survival of patients with CLL and p53 defects identified at our institution by p53 yeast functional assay and complementary interphase fluorescence in situ hybridization analysis detecting del(17p) from 2003 to 2010. Results: A defect of the TP53 gene was identified in 100 of 550 patients. p53 mutations were strongly associated with the deletion of 17p and the unmutated IgVH locus (both P < .001). Survival assessed from the time of abnormality detection was significantly reduced in patients with both missense (P < .001) and nonmissense p53 mutations (P = .004). In addition, patients harboring missense mutation located in p53 DNA-binding motifs (DBMs), structurally well-defined parts of the DNA-binding domain, manifested a clearly shorter median survival (12 months) compared with patients having missense mutations outside DBMs (41 months; P = .002) or nonmissense alterations (36 months; P = .005). The difference in survival was similar in the analysis limited to patients harboring mutation accompanied by del(17p) and was also confirmed in a subgroup harboring TP53 defect at diagnosis. The patients with p53 DBMs mutation (at diagnosis) also manifested a short median time to first therapy (TTFT; 1 month). Conclusion: The substantially worse survival and the short TTFT suggest a strong mutated p53 gain-of-function phenotype in patients with CLL with DBMs mutations. The impact of p53 DBMs mutations on prognosis and response to therapy should be analyzed in investigative clinical trials.

12 April 2013 in Haematologica
Verified
Journal Article
Open access
VNV. Navrkalova
V. Navrkalova
LSL. Sebejova
L. Sebejova
JZJ. Zemanova
J. Zemanova
JKJ. Kminkova
J. Kminkova
BKB. Kubesova
B. Kubesova
MTM. Trbusek
M. Trbusek
ATM abnormalities are frequent in chronic lymphocytic leukemia and represent an important prognostic factor. Sole 11q deletion does not result in ATM inactivation by contrast to biallelic defects involving mutations. Therefore, the analysis of ATM mutations and their functional impact is crucial. In this study, we analyzed ATM mutations in predominantly high-risk patients using: i) resequencing microarray and direct sequencing; ii) Western blot for total ATM level; iii) functional test based on p21 gene induction after parallel treatment of leukemic cells with fludarabine and doxorubicin. ATM dysfunction leads to impaired p21 induction after doxorubicin exposure. We detected ATM mutation in 16% (22 of 140) of patients, and all mutated samples manifested demonstrable ATM defect (impaired p21 upregulation after doxorubicin and/or null protein level). Loss of ATM function in mutated samples was also evidenced through defective p53 pathway activation after ionizing radiation exposure. ATM mutation frequency was 34% in patients with 11q deletion, 4% in the TP53-defected group, and 8% in wild-type patients. Our functional test, convenient for routine use, showed high sensitivity (80%) and specificity (97%) for ATM mutations prediction. Only cells with ATM mutation, but not those with sole 11q deletion, were resistant to doxorubicin. As far as fludarabine is concerned, this difference was not observed. Interestingly, patients from both these groups experienced nearly identical time to first treatment. In conclusion, ATM mutations either alone or in combination with 11q deletion uniformly led to demonstrable ATM dysfunction in patients with chronic lymphocytic leukemia and mutation presence can be predicted by the functional test using doxorubicin.

12 April 2014 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
JMJitka Malcikova
Jitka Malcikova
Evangelia Athanasios StalikaEvangelia Athanasios Stalika
Evangelia Athanasios Stalika
ZDZadie Davis
Zadie Davis
KPKarla Plevova
Karla Plevova
MTMartin Trbusek
Martin Trbusek
KSKostas Stamatopoulos
Kostas Stamatopoulos

18 July 2013
Verified
Book Chapter
Closed access
PDF file
MTMartin Trbusek
Martin Trbusek
JMJitka Malcikova
Jitka Malcikova

27 April 2013 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
APAnna Panovská
Anna Panovská
LSLukas Smolej
Lukas Smolej
DLDaniel Lysak
Daniel Lysak
YBYvona Brychtová
Yvona Brychtová
MŠMartin Šimkovič
Martin Šimkovič
MDMichael Doubek
Michael Doubek